CMS Proposes Coverage With Study Participation For PET In Bone Metastasis
This article was originally published in The Gray Sheet
Executive Summary
CMS is proposing to cover positron emission tomography imaging for identification of bone metastasis in patients with a previously diagnosed solid tumor, but only as part of prospective clinical trials, the agency announced Nov. 30
You may also be interested in...
Physicians Seek Unrestricted Coverage Of NaF-18 PET For Bone Metastasis
Recent shortages of an isotope commonly used in bone scans have prompted several professional societies to urge CMS to offer cancer patients broad access to sodium fluoride-18 positron emission tomography to identify bone metastasis
Physicians Seek Unrestricted Coverage Of NaF-18 PET For Bone Metastasis
Imaging professional societies urge CMS to issue a final national coverage determination allowing use of the agent in cancer patients because of the shortage of Technetium-99m, the only bone imaging agent currently covered.
Physicians Seek Unrestricted Coverage Of NaF-18 PET For Bone Metastasis
Recent shortages of an isotope commonly used in bone scans have prompted several professional societies to urge CMS to offer cancer patients broad access to sodium fluoride-18 positron emission tomography to identify bone metastasis